Objectives: to examine the cost-effectiveness of continued treatment for patients with moderatesevere Crohn's disease in clinical remission, with a combination of anti-TNFα (infliximab) and immunosuppressant therapy compared to two different withdrawal strategies (1) withdrawal of the anti-TNFα therapy, and (2) withdrawal of the immunosuppressant therapy, respectively.
INTRODUCTION
The incidence and prevalence of Crohn's disease (CD) in Western countries range between 5 and 50 per 100 000 inhabitants (Derek et al., 2013) . The healthcare costs associated with CD are considerable (Kappelman et al., 2008) , and patient's with CD suffer from significant quality-of-life reductions, in particular when the disease is active (Cohen, 2002) . Biological treatments, particularly anti-TNF-alpha agents, have been demonstrated to improve treatment outcomes. The most effective therapy for moderate-severe CD is currently a combination of anti-TNF and purine analogues (SONIC trial), which can be considered as the reference standard against which new drugs or drug combinations should be compared. However, the cost of anti-TNF therapy is relatively high (Bodger et al., 2009) , although the introduction of bio-similars has brought the cost down considerably (Schmitz et al., 2017) . The British National Institute for Health and Clinical Excellence has concluded that maintenance therapy using anti-TNF-alpha agents is not a cost-effective approach compared to available treatment alternatives (NICE, 2010) . Furthermore, combination therapy increases the risk of infectious side-effects with a potential of being life-threatening (Toruner, 2008) . Thus, to improve safety and contain costs, treatment regimens that cycle the use of these agents in order to achieve and maintain disease remission are of great interest.
The cost-effectiveness of various treatments for Crohn's disease, using anti-TNF-alpha as monotherapy or in combinations with an antimetabolite, have been estimated an reviewed in a number of studies, for instance Rafia et al. (2016) , Erim et al. (2015) , Saito et al. (2013) , Marchetti et al. (2013) , Tang et al. (2013) and Dretzke et al. (2011) . A recent systematic review of cost-effectiveness studies comparing conventional and biological treatments for inflammatory bowel disease (Pillai et al., 2017) concluded that treatment with infliximab (and adalimumab) in order to maintain remission is not in general cost effective compared to standard treatment in patient with moderate or severe Crohn's disease. However, the cost-effectiveness of a particular treatment strategy depends critically both on the exact content of the strategy and on the comparison alternatives (Tang et al. 2013) . For instance, maintenance treatment with infliximab as monotherapy was found to be cost effective in treatments of patients with moderate to severe Crohn' disease and when limited to one or two years, see, for instance, Bodger et al. (2009) . Only a limited number of studies have compared combination therapy using infliximab and an antimetabolite with either drug as a monotherapy. No published results concerning the cost-effectiveness of maintained combination therapy as compared to treatment strategies in which infliximab and the antimetabolite are withdrawn and reintroduced in case of relapse. The results reported by Marchetti et al. (2013) and Saito et al. (2013) indicate that combination therapy is cost-effective both compared with treatment alternatives that escalate the drug treatment provided, and compared with infliximab as monotherapy. Although there is, to the best of our knowledge, no published results concerning the cost effectiveness of treatment regimens that cycle infliximab and an antimetabolite, the results reported by Saito et al. indicate that sustained combination therapy may be cost effective compared to treatments that withdraw the antimetabolite.
Further, although no cost-effectiveness results concerning infliximab biosimilars could be explicitly identified in the literature, the results in recent studies suggest that costs can be reduced and treatment effectiveness maintained using infliximab biosimilars in the treatment of Chron's disease (Kim et al., 2017; Schmitz et al., 2017) .
No cost-effectiveness results regarding the cost-effectiveness of different withdrawal strategies in which treatment is de-escalated in periods of remission were found in the literature. The objective of this study was to compare the cost-effectiveness of two de-escalation therapies with continued combination therapy using infliximab and an immunosuppressant in patients with Crohn's disease in clinical remission.
DATA AND METHODS
We constructed a Markov-type decision-tree model mimicking three maintenance therapies, including the two de-escalation strategies mentioned above. Thus, in treatment arm 1 the patients continue the combination therapy as previous to randomization. In treatment arm 2, infliximab treatment is withdrawn and anti-metabolites treatment is continued, while in arm 3, infliximab treatment is continued and anti-metabolites withdrawn. Specific calibrations of the provided pharmaceutical treatments in each arm in case of relapse and remission are reported in the detailed illustration in the appendix ( Figures A1 -A3 ).
Simulation model
The simulation model was constructed in order estimate the cost effectiveness of the combination therapy, using an antimetabolite and infliximab, compared to monotherapy using either the antimetabolite or infliximab. The model performs parallel calculations for the three arms using two medical states in each arm, in which the patient is either in remission or in relapse, a one-month clock frequency, and a time horizon of 2 years. In order to infer the effect on cost effectiveness of a longer time horizon the model was extrapolated an additional 5 years. The model is parametrizised with separate relapse risks and remission probabilities for the three arms, state-dependent quality-oflife weights, and state-dependent healthcare costs. The simulation model was populated with parameter values collected from published previous studies (specified below). In cases were the empirical evidence for a specific parametrization is weak, or non-existent, we have complemented our analysis with extensive sensitivity analysis, in order to deduce the significance of the lack of knowledge for the results obtained in this study. The model structure corresponds to the clinical situation illustrated in Figures A1 -A3 , in the appendix. A more detailed description of the input used in the simulation model is provided in the next section.
Health economic evaluation -the cost-effectiveness measure
This study employs firmly established methods for health economic evaluations (Drummond et al., 2015) . The cost-utility analysis provides a method for relating the attained additional treatment effects achieved using a specific intervention (the main alternative) to its additional costs, compared with a specific alternative (the comparison alternative). In principle, this is straightforward, however, in practice it involves several empirical judgements as to what numerical values to use in the calculations. The ratio between cost and effect differences for the compared treatment alternatives is the incremental cost-utility ratio (ICUR), defined as:
In general, the cost variable in the expression above should include not only costs associated with the two treatment alternatives, but also the cost for all other healthcare utilization. Moreover, the costs may also include the indirect effect of the compared treatments on productivity, that is, the effects on sickness absenteeism from work and losses that occur due to premature mortality. The dominant effect measure in a cost-utility analysis captures the number of life years (or any other unit of time) associated with each treatment and the quality of life of each year in a combined measure: The quality adjusted life year (QALY). Since neither costs, nor quality of life, can be measured unobjectionably, the reporting of results should be complemented with an analysis of how the core measure, the ICUR, is affected by alternative quality-of-life-and cost measures (deterministic sensitivity analysis). Beyond these measurement issues, there is also the question of to what extent the parameters that enters into the ICUR measure are afflicted with uncertainty. That is, the effects of a treatment and the associated healthcare costs may contain random components. This may be dealt with using probabilistic analysis.
Given a set of values reflecting costs and effects of two competing treatment alternatives, the incremental cost-utility ratio provides a measure of the incremental cost per QALY associated with the main treatment alternative. Whether or not the main treatment alternative should be regarded as being "cost effective" as compared with the comparison alternative depends on the societal willingness-to-pay for an additional QALY. So, if the incremental cost per QALY gained by using the main treatment alternative instead of the comparison alternative is below that threshold value, the main alternative is to be considered as cost effective (see the appendix for an elaboration of these concepts). The informal willingness-to-pay threshold in Sweden is 500 000 SEK/QALY.
Input data
This section describes the data collection processes and sources. A summary of the base-case numerical specification of the simulation model is reported in Table 1 . Specifications as to the probabilistic sensitivity analysis are also provided in Table 1 .
Clinical effectiveness
The simulation model incorporates two different parameters reflecting clinical effectiveness, the risk of relapse and the likelihood of remission. Information about these clinical effectiveness parameters was collected for each treatment arm separately. The proportion of the patient population that relapse within 24 months (risk of relapse) were used to calculate the monthly relapse rate in each treatment arm (Adegbola et al., 2018; Boyapati et al., 2018; Fria Gomes et al., 2018; Torres et al., 2015; Louis et al., 2012) . Relapse rates and remission likelihoods in arm 1 and 3 were assumed to be constant over time, while the relapse rater in arm 2 (infliximab withdrawal) was calculated separately for three consecutive time intervals, 2 -8 months, 9 -14 months, and 15 -24 month, using the information that about 50 % of the patients relapse within 24 months (for details, see Table 1 ). The likelihood of remission after a relapse was assumed to be 65 % in arm 1 (Baert et al., 2013; Chaparo et al., 2011; Steenholdt et al., 2015) , and 70 % in arm 3 (after infliximab escalation and reintroduction of the antimetabolite) (Baert et al., 2013; Chaparo et al., 2011; Ungar et al., 2017) . The corresponding likelihoods in arm 2 were assumed to be 80 % and 90 %, respectively, for the reinstatement of infliximab at 5 mg and 10 mg (Kennedy et al., 2016; Torres et al., 2015) . in which infliximab is withdrawn (see Table 1 ).
Quality of life
Quality-of-life weights were collected from Saito et al. (2013) , Table 1 , Quality of life utilities; utility weights for the health states Remission (remission in our model), Mild disease (relapse in our model),
and Non-responding active disease (failure in our model).
Pharmaceutical treatment costs
Pharmaceutical treatment costs were calculated using Swedish unit costs (The Dental and Pharmaceutical Benefits Agency) for 2017. The monthly pharmaceutical treatment costs were estimated at SEK 4 924 (infliximab 5 mg), SEK 9 849 (infliximab 10 mg), and SEK 210 (antimetabolites). Pharmaceutical treatment costs in case of treatment failure are assumed to correspond to combination treatment with infliximab 10 mg and antimetabolites.
Medical treatment costs
Medical treatment costs comprise costs associated with outpatient visits and hospitalizations, with and without surgery. Every relapse was assumed to result in either one outpatient visit to hospital clinic, in 90 % -95 % of the cases, or in hospitalization, in 5 % -10 % of the cases. Between 0 % and 3 % of the hospitalized were assumed to be subject to surgery. The corresponding figures for those characterized as treatment failures, were 70 % -80 % are hospitalized and between 3 % and 10 % subject to surgery. No distinctions between treatment arms were considered.
Unit costs were collected from the diagnosis-related groups (DRG) statistics issued by the Swedish National Board of Health and Welfare. The DRG statistics report DRG weights for every medical procedure, and a cost per a one-unit weight (SEK 54 254). Thus, the unit cost for surgery used in our calculations was calculated as the weighted sum of DRG weights for bowel surgery without complications, with complications and with severe complications. The unit cost for surgery was estimated at SEK 158 313. The unit costs for inpatient-and outpatient care visits were estimated as the costs corresponding to the DRG weights for inpatient-and outpatient care due to inflammatory bowel disease, SEK 42 915 and SEK 4 774, respectively.
Discounting
Following the guidelines issued by National Institute for Health and Care Excellence (NICE), costs and effects were discounted monthly at a 3.5 % annual discount rate.
Sensitivity analysis
We performed both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis, pertaining to the core parameters of the simulation model.
Deterministic sensitivity analysis
We performed one-way deterministic sensitivity analysis for ∓ 10 % variation of (1) the relapse rate for patients treated with a combination therapy, in either treatment arm, (2) relapse rates for monotherapies with infliximab or an immunosuppressant, (3) the remission rates for the infliximab 10 mg monotherapy and the combination therapy alternatives, and (4) utility weights for the states remission, relapse, and failure, (5) healthcare costs associated with relapse and treatment failure, respectively, and (6) pharmaceutical (infliximab) costs. Additional sensitivity analyses were performed for (1) the impact of infliximab price reductions on the cost effectiveness of combination therapy were performed, and (2) the relapse rate associated with infliximab withdrawal.
Probabilistic sensitivity analysis
Data on treatment effectiveness, and the associated healthcare utilization, comprises uncertainty due to the fact that a given treatment does not guarantee a specific outcome. Deterministic sensitivity analysis is useful for examining the range of a specific parameter for which the incremental costutility ratio falls below a specified threshold value, but it produces no information as to the probability of achieving a cost-utility ratio which falls below that threshold value. The distribution of the ICUR can be calculated employing Monte Carlo simulations or bootstrapping (Drummond et al., 2015) .
The Monte Carlo approach involves specifying statistical distributions for the parameters that are examined, while the bootstrapping method relies on random sampling with replacement from primary data. Thus, while Monte Carlo simulation imposes additional assumptions on the data generation process the bootstrapping method does not. Simulations with either method will produce an estimate of the distribution of the ICUR. In this study, we used Monte Carlo simulations, since primary data for the clinical trial is not yet available.
Monte Carlo simulations involving all relapse rates, remission likelihoods, and healthcare costs were performed. Adopting the method for performing probabilistic sensitivity analysis outlined by Briggs et al. (2006) the following assumptions were made: (1) all probabilities were assumed to be Betadistributed, and (2) healthcare costs were assumed to be lognormally distributed (for details, see Table 1 ). +++ Monthly treatment cost in case of treatment failure is 9 849 + 210. * 10 % of the patient population is relapsing within 24 months. Assuming a constant rate, r, of relapsing we have: (1 − ) 24 = 0.9; ** calculated assuming that 50% of the patients relapse over the 24-months trial, and that 50% of the patients relapsing do so between months 2 and 8, 25% of the patients relapse between month 9 and 14, and 25 % of the patients relapse between months 9 and 24. *** 20 % of the patient population is relapsing within 24 months. Assuming a constant rate, r, of relapsing we have: (1 − ) 24 = 0.8; **** 70 % of patient gain remission after infliximab escalation to 10 mg and reintroduction of AZA. Assuming that 60 % regain remission after the escalation of infliximab. Thus, the additional remission rate, , is given by 0.6 + (1 − 0.6) • = 0.7
RESULTS
The results are presented in Table 2 . For the base-case input data (Table 1) , the following outcomes are reported for the 24-month period (per 1000 patients): (1) total incremental intervention cost (the additional pharmaceutical cost imposed by combination treatment compared to discontinuing infliximab and to discontinuing anti-metabolites, respectively), (2) total healthcare costs averted (additional healthcare costs accruing from treatment failure), (3) total QALYs gained (the number of life years gained adjusted for the gain in quality of life obtained by combination treatment), and (4) the incremental cost per QALY gained.
Base-case
Combination treatment is more costly and more efficient than treatment involving discontinuing infliximab. The incremental cost-effectiveness ratio was estimated at 755 449 SEK per additional quality-adjusted life year and, hence, combination treatment is not cost-effective compared with the withdrawal of infliximab, using a 500 000 SEK/QALY threshold. Comparing combination treatment with treatment involving discontinuing antimetabolites shows that combination treatment is both less costly and more efficient, resulting in savings per additional quality-adjusted life year. Thus, for a willingness-to-pay threshold for an additional QALY, maintained combination treatment is costeffective compare with withdrawing the metabolite and withdrawing infliximab, respectively. 
Sensitivity analyses
The incremental cost-effectiveness ratio was relatively insensitive to ∓ 10 % variations (from basecase values) in the input variables except the unit cost of infliximab, as can be seen from the reporting of the deterministic sensitivity analysis, Table 3 . Thus, the qualitative content of the basecase results -that maintained combination treatment is cost effective compared to the withdrawal of the antimetabolite and not cost effective compared to the withdrawal of infliximab -were unaltered by the univariate changes considered. The parameterization of the remission likelihoods in arm 3
(discontinuing the antimetabolite) was particularly inflicted with uncertainty and, hence, we performed additional sensitivity analyses in this case. Varying the remission likelihoods associated with infliximab escalation and reintroduction of the antimetabolite, respectively, by ∓ 50 % from base-case values (60 % and 25 %) resulted in lower costs and additional QALYs for the combination treatment alternative in both cases, and, hence, the qualitative result that maintaining combination therapy both saves resources and produces more QALYs is robust. Moreover, since the price of infliximab can be expected to decrease in the future, as the utilization of biosimilars increase, we calculated incremental cost-effectiveness ratios for a range of infliximab prices (per 100 mg). The result is illustrated in Figure 7 . The infliximab price-threshold for when the combination therapy will be assessed as being cost effective at SEK 1 865/100 mg.
In addition to the sensitivity analyses reported in Table 3 , we explored the scenario in which patients who have either a low or a high risk (in relation to the base-case 20 %) of relapse when infliximab is withdrawn can be identified. We estimated the threshold share of patients who relapse within 24 month when infliximab is withdrawn which would make this treatment alternative cost effective compared to continued combination therapy: if 12,8 % (or less) of the patients relapse (within 24 month), infliximab withdrawal produces better quality-of-life outcomes at a lower cost than continued combination therapy. If 60 % (or more) of the patients relapse when infliximab is withdrawn, the combination therapy becomes cost effective. Further, we extrapolated the costeffectiveness results to a 7-year time perspective, assuming that 80 % of the patients relapse over this period and that all other relapse risks and remission likelihoods remain the same. These calculations show that the incremental cost per QALY increases with the time horizon for the comparison between continued combination therapy and infliximab withdrawal. Combination therapy stays more efficient and less costly than antimetabolite withdrawal. Probabilistic sensitivity analysis were performed for 10 000 random draws of the simulated at SEK 755 449 and -SEK 79 933 (lower cost and higher effect), respectively. Thus, the combination therapy is not cost-effective as compared to the withdrawal treatment strategy, for the threshold of the willingness-to-pay for an additional QALY that is usually applied in Sweden.
DISCUSSION
We analyzed the cost-effectiveness of a combination treatment for patients with Crohn's disease as compared to two withdrawal/reintroduction strategies, using a two-year time perspective. The medical scientific literature does not provide information on the clinical effectiveness parametersrelapse and remission rates -corresponding exactly to the clinical situations that were compared in this study. Instead, the cost-effectiveness calculations were performed applying parameter values collected from clinical studies corresponding closely to the treatments compared here. This approach was complemented with extensive analyses of the sensitivity of the cost-effectiveness measure to the parameter values.
In the near future primary treatment effectiveness data will be available. The treatment alternatives compared in this study correspond to the three treatment alternatives studied in the on-going SPARE trial, which is an open label, multicenter, trial with three parallel arms, in which patients who are in sustained clinical remission without steroids for at least six months, and have been treated by a combination of antimetabolites and infliximab for at least one year prior to enrollment, are randomized to one of three maintenance therapies. The SPARE trial study design corresponds to the clinical situation illustrated in Figures A1 -A3 in the appendix. In treatment arm 1 the patients continue the combination therapy as previous to randomization. In treatment arm 2, infliximab treatment is withdrawn and anti-metabolites treatment is continued, while in arm 3, infliximab treatment is continued and anti-metabolites withdrawn. In all treatment arms the pharmaceutical treatment is modified in response to relapse and attained remission. To the best of our knowledge, this is the first study which attempt to estimate the cost-effectiveness of maintained combination treatment, as compared to drug withdrawal and reintroduction/reescalation in case of relapse, in patients with Crohn's disease. Saito et al. (2013) calculated the cost-effectiveness of induction and maintenance treatment with infliximab in combination with azathioprine as compared to induction and maintenance treatment with infliximab as mono-therapy at about SEK 45 000. Our setting is not identical to the clinical setting analyzed by Saito et al., but the similarities between ours and their setting renders the observation that their estimated cost-effectiveness is in the same range as our figure significance.
The sensitivity analyses performed showed that the estimated cost-effectiveness of the combination therapy, as compared to the two withdrawal treatment strategies, is relatively insensitive to changes in the parameters values used in the calculations. The intuitive explanation for this finding is that, except for risks of relapse, all parameters appear in the cost and effect calculations in all treatment arms. For instance, since infliximab is used by some share of patients in all arms, the effect of an infliximab price change for the treatment cost in arm 1 will be partly offset by a corresponding price change in the comparator arm. Figure A2 . Treatment arms 2 (discontinuing infliximab) Assumptions about relapse and remission risks and probabilities: relapse risks are different for 2 -8 months, 9 -14 months, and 15 -25 months after randomization. Risks are calculated for these time intervals in accordance with previously discussed diminishing risk over time. After a relapse, once the patient enters the lower part of the three structure, the risk of relapse is the same as before the first relapse, i.e., the risk of relapse depends on time only. The justification for this is that after a relapse and subsequent remission the patient returns to the baseline treatment of the treatment arm. The probability of remission from a relapse depends on the treatment intensification. So, for example, the probability of remission differs from AZA+5 mg IFX and AZA + 10 mg IFX. Quality of life weights are assumed independent on treatment paths and depend on the state only. Three different quality-of-life weights are incorporated: for the no relapse/remission state, the relapse state, and the treatment failure state. 
